1. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer 2017; 17: 513-527.
2.
Curtis RE, Boice Jr JD, Stovall M, Bernstein L, Greenberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N En J Med 1992; 326: 1745-1751.
3.
Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 2013; 121: 2996-3004.
4.
Pedersen-Bjergaard J, Philip P, Mortensen BT, Ersbøll J, Jensen G, Panduro J, et al. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Clinical and cytogenetic characteristics and results of in vitro culture of bone marrow and HLA typing. Blood 1981; 57: 712-723.
5.
Kantarjian HM, Keating M, Walters R, Smith T, Cork A, McCredie K, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 1748-1757.
6.
Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005; 23: 4179-4191.
7.
Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045-1047.
8.
Krajnak S, Battista MJ, Hasenburg A, Schmidt M. Metronomic chemotherapy for metastatic breast cancer. Oncol Res Treat 2022; 45: 12-17.
9.
Cazzaniga M, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M, et al. Metronomic chemotherapy in triple-negative metastatic breast cancer: the future is now? Int J Breast Cancer 2017; 2017: 1683060.
10.
Cazzaniga M, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, et al. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. Breast Cancer Res Treat 2021; 190: 415-424.
11.
Gagnier JJ, Riley D, Altman DG, Moher D, Sox H, Kienle G. The CARE Guidelines. Dtsch Ärztebl Int 2013; 110: 603-608.
12.
Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
13.
Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87: 515-526.
14.
Montagna E, Pagan E, Cancello G, Sangalli C, Bagnardi V, Munzo- ne E, et al. The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. Anti-Cancer Drugs 2022; 33: e628-e34.
15.
Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006; 17: 961-967.
16.
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 2018; 29: 1634-1657.
17.
Cazzaniga ME, Capici S, Cordani N, Cogliati V, Pepe FF, Riva F, et al. Metronomic chemotherapy for metastatic breast cancer treatment: clinical and preclinical data between lights and sha-dows. J Clin Med 2022; 11: 4710.
18.
Greenberg PL, Stone RM, Abaza Y, Al-Kali A, Anand S, Ball B, et al. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2025; 23: 66-75.
